BACKGROUND Patients with an implantable cardioverterdefibrillator (ICD) are at a high risk of malignant ventricular arrhythmias. The use of remote ICD monitoring, wearable devices, and patient-reported outcomes generate large volumes of potential valuable data. Artificial intelligence-based methods can be used to develop personalized prediction models and improve earlywarning systems.OBJECTIVE The purpose of this study was to develop an integrated web-based personalized prediction engine for ICD therapy
Q6. METHODS This international, multicenter, prospective, observational study consists of 2 phases: (1) a development study and (2) a feasibility study. A total of 400 participants with an ICD (with or without cardiac resynchronization therapy) on remote monitoring will be enrolled: 300 participants in the development study and 100 in the feasibility study. During 12-month followup, electronic health record data, remote monitoring data, accelerometry-assessed physical behavior data, and patientreported data are collected. By using machine-and deep-learning approaches, a prediction engine is developed to assess the risk probability of ICD therapy (shock and antitachycardia pacing). The feasibility of the prediction engine as a clinical tool (SafeHeart Q7 Platform) is assessed during the feasibility study. RESULTS Development study recruitment commences in 2021 Q8 . The feasibility study starts in 2022 Q9 .CONCLUSION SafeHeart is the first study to prospectively collect a multimodal data set to construct a personalized prediction engine for ICD therapy. Moreover, SafeHeart explores the integration and added value of detailed objective accelerometer data in the prediction of clinical events. The translation of the SafeHeart Platform to clinical practice is examined during the feasibility study.